BioCryst Pharmaceuticals, Inc. (BCRX)
NMS – Real Time Price. Currency in USD
10.56
+0.21 (2.08%)
Market open: Aug 12, 2026, 2:40 PM EDT
10.23
-0.11 (-1.06%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
10.56
+0.21 (2.08%)
Market open: Aug 12, 2026, 2:40 PM EDT
10.23
-0.11 (-1.06%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Total debt $836.6M significantly exceeds cash reserves ($155.5M), raising financial stability concerns
Total current assets $484.7M exceed Total current liabilities $208.8M, highlighting excellent liquidity
Debt-to-equity ratio (-1.8) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (5x) indicates the company easily manages its debt payments
The company generates positive free cash flow $103.8M, supporting its financial health
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.32 | 2.52 | 10 | |
| Quick ratio | 2.29 | 1.78 | 10 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | 1.50 | 0.73 | 1.0 | |
| Interest coverage | 4.54 | -13.90 | 10 | |
| Weighted average score | 6.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 271M | 331M | 451M | 875M | 941M |
| Gross Profit | 263M | 325M | 437M | 854M | 917M |
| Operating Income | -148M | -104M | -3M | 341M | 385M |
| Net Income | -247M | -227M | -89M | 264M | -385M |
| EBITDA | -147M | -102M | -1M | 342M | 387M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 3.75 | 53.32 | 7.0 |
| Next quarter | -58.38 | -89.52 | 1.0 |
| Current year | -19.58 | -290.21 | 1.0 |
| Next year | 5.32 | 123.87 | 7.5 |
| Weighted average score | 4.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 39.53 | 110.86 | 110.07 | 265.93 | 10 |
| Y/Y | 33.61 | 1441.69 | 1400 | 155.68 | 10 |
| 3y average | 50.82 | 155.32 | 152.08 | 267.28 | 10 |
| 5y average | 201.43 | 86.21 | 86.52 | 156.8 | 10 |
| Weighted average score | 10 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |